HOME > Scientific Program > Invited Speakers

Invited Speakers

Leonardo M. Fabbri
Leonardo M. Fabbri
University of Modena & Reggio Emilia, Italy
biography
Nicola A. Hanania
Nicola A. Hanania
Bayolaor College of Medicine, USA
biography
Richard Casaburi
Richard Casaburi
University of California, Los Angeles (UCLA), USA
biography
Maciej Kupczyk
Maciej Kupczyk
Medical University of Lodz, Poland
biography
Victor Kim
Victor Kim
Temple University School of Medicine, USA
Allison Lambert
Allison Lambert
Johns Hopkins University, USA
Chunxue Bai
Chunxue Bai
Zhongshan Hospital, Fudan University, China
biography
Yoshiharu Ohno
Yoshiharu Ohno
Kobe University Graduate of Medicine, Japan
Sang Do Lee
Sang Do Lee.jpg
Asan Medical Center, Korea
Yeon Mok Oh
Yeon Mok Oh.jpg
Asan Medical Center, Korea
Young Sam Kim
Young Sam Kim.jpg
Yonsei University, Severance Hospital, Korea
Chin Kook Rhee
Chin Kook Rhee.jpg
Seoul St. Mary's Hospital, Korea
Yong Beom Park
Yong Beom Park.jpg
Kangdong Sacred Heart Hospital Hallym University, Korea
Hye Sook Choi
Hye Sook Choi.jpg
Dongguk University Gyeongju Hospital, Korea
Joon Beom Seo
Joon Beom Seo.jpg
Asan Medical Center, Korea
Yu Il Kim
Yu Il Kim.jpg
Chonnam National University Hospital, Korea
Yong Beom Shin
Yong Beom Shin.jpg
Pusan National University Hospital, Korea
An Soo Jang
An Soo Jang.jpg
Soonchunhyang University Hospital, Korea
Sang Heon Kim
Sang Heon Kim.jpg
Hanyang University Seoul Hospital, Korea
Woo Jung Song
Woo Jung Song.jpg
Seoul National University Hospital, Korea
Tae Hoon Lee
Tae Hoon Lee.jpg
Ulsan University Hospital, Korea
Hye Ryun Kang
Hye Ryun Kang.jpg
Seoul National University Hospital, Korea
Chang Hyun Lee
Chang Hyun Lee.jpg
Seoul National University Hospital, Korea
Heon Sil Kim
Heon Sil Kim.jpg
Asan Medical Center, Korea
Ji Yeon Min
Ji Yeon Min.jpg
Asan Medical Center, Korea
Leonardo M. Fabbri
사진이미지
University of Modena & Reggio Emilia, Italy
Leonardo M. Fabbri, Professor of Respiratory Medicine; Honorary Professor of Internal Medicine, Director of the Department of Department of Oncology, Haematology and Respiratory Diseases, University of Modena and Reggio Emilia; he received doctorate in Medicine and Surgery, University Padua in 1972 (110/110 summa cum laude), Board in Occupational Medicine, University Padua in 1975 (70/70 summa cum laude), Board of Respiratory Medicine, University Bologna in 1978 (70/70 summa cum laude). Visiting Research Fellow, Department of Respiratory Diseases, Tulane University (1980-1981) and at Cardiovascular Research Institute, University California, San Francisco, USA (1981-1983). Served as Chief Editor for European Respiratory Review and of the European Respiratory Monograph and as is still Associate Editor of the European Respiratory Journal and of the American Journal of Respiratory and Critical Care Medicine, Lancet Respiratory Medicine, European Journal of Clinical Investigation. He was member of the Executive Committee of the Global Initiative on Asthma (GINA) (1990–2001); member of Scientific Committee of Global Initiative on Obstructive Lung Disease (GOLD) (1997-2005, and 2009-to date); Chairman of Scientific Committee, GOLD (2001-2004); member of Workshop Panel of GOLD (2001-2005); chairman of Executive Committee GOLD (2004 – 2005), and back again in the Scientific Committee 2009-ta date. He was President of the European Respiratory Society (ERS) 2007-2008. He has published > 350 papers in peer reviewed journal plus several book chapters.
top
Nicola A. Hanania
사진이미지
Bayolaor College of Medicine, USA
Nicola A. Hanania, MD, MS is Associate Professor of Medicine in the Section of Pulmonary and Critical Care Medicine and Director of the Asthma and COPD Clinical Research Center at the Baylor College of Medicine in Houston, Texas, USA. He completed his medical training at the University of Jordan followed by residency in internal medicine and a fellowship in pulmonary medicine at the University of Toronto, Canada. He subsequently completed a fellowship in critical care medicine at Baylor College of Medicine, where he later earned a master’s degree in clinical investigation.

As a Fellow of the American College of Chest Physicians, Dr. Hanania has served on the Board of Regents and as Chair of the Clinical Pulmonary, Airways Networks and Council of Networks for this organization. He has been on the Board of Trustees of the Chest Foundation since 2012. In addition, he is a current member of the Health Policy Committee of the American Thoracic Society, the European Respiratory Society, the Society of Critical Care Medicine and a fellow of the Royal College of Physicians and Surgeons of Canada. He has served on several guideline and workshop panels including the ACP/ATS/ACCP/ERS Clinical Practice guidelines on COPD and the CTS/ACCP COPD exacerbations guidelines.

Dr. Hanania has received multiple awards including the ACCP’s Distinguished Scholar in Respiratory Health, ACCP Humanitarian Award, Career Investigator Award (K23) from the NIH, Fulbright and Jaworski’s Faculty Excellence Award for Teaching and Evaluation and the Award for Excellence in Teaching from the Department of Medicine at Baylor. Baylor also named him to the Academy of Distinguished Educators for 2003-2010. Dr. Hanania is a deputy editor of Respiratory Medicine and is Associate Editor of Therapeutic Advances in Respiratory Disease, Current Opinion in Pulmonary Medicine (Asthma Section) and Pulmonary Pharmacology and Therapeutics.

Dr. Hanania’s research interests focus on the pharmacology and management of asthma and COPD. He has published more than 200 peer-reviewed papers, book chapters, editorials and reviews on these topics. He is actively involved in clinical trials investigating novel treatments. He is Principal Investigator for the American Lung Association Airway Clinical Research Center at Baylor College of Medicine, as well as Principal Investigator or Co-Investigator in several clinical trials in asthma and COPD. He has been invited and has lectured widely at local, regional, national and international meetings.
top
Richard Casaburi, PhD, MD
사진이미지
University of California, Los Angeles (UCLA), USA
Richard Casaburi is Professor of Medicine at the UCLA School of Medicine and Associate Chief for Research in the Division of Respiratory Medicine at Harbor-UCLA Medical Center in Torrance, California. He occupies the Grancell/Burns Endowed Chair in the Rehabilitative Sciences at the Los Angeles Biomedical Research Institute.

Dr. Casaburi completed his PhD in biomedical engineering from Rensselaer Polytechnic Institute and a post-doctoral fellowship at the University of Southern California. Five years after joining the Harbor-UCLA faculty, he returned to school to pursue his medical degree at the University of Miami. He returned to Harbor-UCLA Medical Center to complete his pulmonary medicine training and then rejoined the Respiratory Medicine faculty. He became Chief of the Division in 1998 and served in this position for six years. He served as Director of the Clinical Respiratory Physiology Laboratories at Harbor-UCLA for 25 years.

Dr. Casaburi established the Rehabilitation Clinical Trials Center in 1999, a facility dedicated to COPD clinical research; this group moved into a new purpose-built research facility, the Chronic Disease Clinical Research Center in 2012. He has completed more than 75 clinical research studies, including participation in 3 major NIH multicenter projects. He has published more than 260 papers and 240 abstracts and has presented over 500 invited lectures on respiratory physiology, exercise science, pulmonary rehabilitation and COPD therapeutics.

Dr. Casaburi serves as president of the Pulmonary Education and Research Foundation, a non-profit corporation dedicated to advancing the scientific basis of pulmonary rehabilitation.
top
Maciej Kupczyk
사진이미지
Medical University of Lodz, Poland
The main directions of Maciej Kupczyk’s scientific interests and current research include issues related to severe asthma, the search for new biomarkers of respiratory diseases, hypersensitivity to drugs and specific immunotherapy. In addition to carrying out studies included in the series of publications discussed above he participate in the research work of several European and national research teams. In the project EARIP (European Asthma Research and Innovation Partnership, EP7) He is working on the development of a list of the key objectives for future research in the field of asthma and on identifying the most pressing problems from the point of view of the practical care of patients with asthma. In the consortium U- BIOPRED and project CHAMP main directions of his research include the search for new biomarkers of asthma, primarily in the severe form of the disease, markers that possibly correlate with a clinical phenotype or endotype of asthma, with the need for medication or that correlate with the duration of the disease, according to the principles of personalized medicine. Similarly, in the project entitled "MicroRNAs as new biomarkers of respiratory tract diseases", in which he is the main contractor, his work is focused on the search for new biomarkers (among microRNAs) in asthma, chronic sinusitis, sarcoidosis, and cancers of the upper respiratory tract. This project is run in collaboration with several clinical centers in Poland (Prof. Adam Antczak, MD, PhD, Wojciech Piotrowski, MD, PhD, Department of Pulmonology and Allergology, Medical University of Lodz , prof. Violetta Pietruszewska, MD, PhD, Department of ENT and ENT Oncology) and several centers of basic research in the European Union (Carsten Daub MD, PhD, SciLife Lab, Karolinska Institutet, Stockholm, Sweden, and Professor Guy Brusselle MD, PhD, Laboratory for Translational Research in Obstructive Pulmonary Diseases, University of Ghent, Belgium). He continues to work on the evaluation of clinical efficacy and safety of new therapies (including but not limited to omalizumab, a humanized monoclonal anti-IgE antibody) in severe asthma. In collaboration with Professor Miroslawa Pietruczuk MD, PhD they conduct research on the role of regulatory cells, T lymphocytes, and adipocytokines in patomechanisms of asthma. Within the field of the specific allergen immunotherapy his interests are currently focused on the issues of the safety of this therapy methods (analysis of early and late side effects), including immunotherapy for Hymenoptera venom. Another area of his interests covers the search for new markers of clinical efficacy of immunotherapy. He leads also works on safety analysis of diagnostic tests in allergen nasal challenge in allergic rhinitis before qualifying for specific allergen immunotherapy.
top
Mark T. Dransfield
사진이미지
University of Alabama at Birmingham, USA
Dr. Dransfield’s primary research interest is COPD and his efforts have focused on epidemiologic and translational studies of the disease as well the conduct of clinical trials testing existing and novel therapies. He is an internationally recognized expert in the design and execution of COPD clinical trials and serves as the lead PI for an $11 million multicenter clinical trial of beta blockers in COPD recently funded by the Department of Defense as well as the UAB PI of the NIH sponsored COPD Clinical Research Network, Spiromics and COPD Gene projects. He is also co-investigator for the Long Term Oxygen Treatment Trial and four R01 projects as well as PI for multiple internally funded and pharma sponsored studies including translational projects involving quantitative CT scan analysis as well as the collection and analysis of biological samples (including those obtained through bronchoscopy). He also serves as the Medical Director of the UAB Lung Health Center (LHC) and oversees its research, educational and clinical activities. The LHC encompasses approximately 11,300 square feet of laboratory and clinical research space and employs 12 full and part time staff including research coordinators, respiratory therapists, and administrative personnel. The LHC houses cores in Human Pulmonary Function, Recruitment, and Regulatory Support as well as a Biospecimen Repository and has collaborations on campus for the performance of proteomics, synthetic chemistry, Luminex, and murine pulmonary function testing and specimen analysis. The LHC is currently conducting more than 20 clinical trials in COPD and asthma.
top
Chunxue Bai
사진이미지
Zhongshan Hospital, Fudan University, China
Dr Bai established CALC (Chinese Alliance Against Lung Cancer) in 2012 and launched a campaign of HTH with opening hundred sub-centers, educating thousand specialists for diagnosis and treatment over hundred thousand cases of early stage lung cancer from pulmonary nodules each year. Dr. Bai is known for his pioneering work of e-health and his cell phone-based remote monitoring system for lung function and has been included in Who’s Who at ATS. He has authored more than 500 papers, including 150 papers in SCI indexes and 30 book chapters
top